The joint in vitro action of polymyxin B and miconazole against pathogens associated with canine otitis externa from three European countries

Veterinary Dermatology

Volumn 24, Issue 4, 2013, Pages

  Pietschmann, Silvia ^a,b   Meyer, Michael ^c   Voget, Michael ^b   Cieslicki, Michael ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ECON GmbH   (Germany)

^c BEUTH UNIVERSITY OF APPLIED SCIENCES   (Germany)

^d LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; MICONAZOLE; POLYMYXIN B;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG POTENTIATION; EUROPE; EXTERNAL OTITIS; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; DOG DISEASES; DOGS; DRUG SYNERGISM; EUROPE; MICONAZOLE; OTITIS EXTERNA; POLYMYXIN B;

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; ESCHERICHIA COLI; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS PSEUDINTERMEDIUS;

EID: 84880331055     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/vde.12037     Document Type: Article

References (40)

1. Oliveira LC, Leite CA, Brilhante RS et al. Comparative study of the microbial profile from bilateral canine otitis externa. Can Vet J 2008; 49: 785-788.
2. Studdert VP, Hughes KL. A clinical-trial of a topical preparation of miconazole, polymyxin and prednisolone in the treatment of otitis-externa in dog. Aust Vet J 1991; 68: 313-314.
3. Engelen MA, Anthonissens E. Efficacy of non-acaricidal containing otic preparations in the treatment of otoacariasis in dogs and cats. Vet Rec 2000; 147: 567-569.
4. Rougier S, Borell D, Pheulpin S et al. A comparative study of two antimicrobial/anti-inflammatory formulations in the treatment of canine otitis externa. Vet Dermatol 2005; 16: 299-307.
5. Engelen M, De Bock M, Hare J et al. Effectiveness of an otic product containing miconazole, polymyxine B and prednisolone in the treatment of canine otitis externa: multi-site field trial in the US and Canada. Intern J Appl Res Vet Med 2010; 8: 21-30.
6. Van Cutsem JM, Thienpont D. Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy 1972; 17: 392-404.
7. Schwartz SN, Medoff G, Kobayashi GS et al. Antifungal properties of polymyxin B and its potentiation of tetracycline as an antifungal agent. Antimicrob Agents Chemother 1972; 2: 36-40.
8. Gale EF, Cundliffe E, Reynolds PE et al. The Molecular Basis of Antibiotic Action. 2nd edn. London: Wiley & Sons, 1981: 175-257.
9. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1: 156-164.
10. Vaara M. Agents that increase the permeability of the outer membrane. Micobiol Rev 1992; 56: 395-411.
11. Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. J Clin Microbiol Rev 2008; 21: 449-465.
12. Molina J, Cordero E, Pachón J. New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacother 2009; 10: 2811-2828.
13. Moneib NA. In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. J Chemother 1995; 7: 525-529.
14. Cornelissen F, Van den Bossche H. Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B. Chemotherapy 1983; 29: 419-427.
15. Pietschmann S, Hoffmann K, Voget M et al. Synergistic effects of miconazole and polymyxin B on microbial pathogens. Vet Res Commun 2009; 33: 489-505.
16. Isham N, Ghannoum MA. Antifungal activity of miconazole against recent Candida strains. Mycoses 2010; 53: 434-437.
17. Fothergill AW. Miconazole: a historical perspective. Expert Rev Anti Infect Ther 2006; 4: 171-175.
18. Moore RA, Chan L, Hancock RE. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 26: 539-545.
19. Junco MTT, Barrasa JLM. Identification and antimicrobial susceptibility of coagulase positive staphylococci isolated from healthy dogs and dogs suffering from otitis externa. J Vet Med B Infect Dis Vet Public Health 2002; 49: 419-423.
20. Hariharan H, Coles M, Poole D et al. Update from antimicrobial susceptibilities of bacterial isolates from canine and feline otitis externa. Can Vet J 2006; 47: 253-255.
21. Landman D, Bratu S, Alam M et al. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005; 55: 954-957.
22. Yau W, Owen RJ, Poudyal A et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009; 58: 138-144.
23. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66: 2070-2074.
24. Devriese LA, Vancanneyt M, Baele M et al. Staphylococcus pseudintermedius sp. nov., a coagulase-positive species from animals. Int J Syst Evol Microbiol 2005; 55: 1569-1573.
25. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically: Approved Standard. Document M7-A8. 8th edn. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
26. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
27. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available at: www.r-project.org/. Accessed Dec 10, 2012.
28. Jones RN, Anderegg TR, Swenson JM et al. Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J Clin Microbiol 2005; 43: 925-927.
29. Fung JC, McKinley G, Tybursky MB et al. Growth of coagulase-negative staphylococci on colistin-nalidixic acid agar and susceptibility to polymyxins. J Clin Microbiol 1984; 19: 714-716.
30. Boyen F, Verstappen KM, De Bock M et al. In vitro antimicrobial activity of miconazole and polymyxin B against canine meticillin-resistant Staphylococcus aureus and meticillin-resistant Staphylococcus pseudintermedius isolates. Vet Dermatol 2012; 23: 381-385.
31. Pankey GA, Sabath LD. Clinical relevance of bacteristatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004; 38: 864-870.
32. Alder J, Eisenstein B. The advantage of bactericidal drugs in the treatment of infection. Curr Infect Dis Rep 2004; 6: 251-253.
33. The Merck Veterinary Manual. Available at: www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/70900.htm. Accessed Dec 10, 2012.
34. Bergen PJ, Li J, Nation RL et al. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Chemotherapy 2008; 61: 636-642.
35. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009; 49: 271-274.
36. Vaara M, Porro M. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother 1996; 40: 1801-1805.
37. Nobre LS, Todorovic S, Tavares AFN et al. Binding of azole antibiotics to Staphylococcus aureus flavohemoglobin increases intracellular oxidative stress. J Bacteriol 2010; 192: 1527-1533.
38. Instructions to authors. Antimicrob Agents Chemother 2005; 49: 1-20. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1305751/. Accessed Dec 10, 2012.
39. Meletiadis J, Pournaras S, Roilidis E et al. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. J Antimicrob Agents Chemother 2010; 54: 602-609.
40. European Medicines Agency, Veterinary Medicines. European Public Report. Easotic. 2008. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/veterinary/000140/WC500063875.pdf. Accessed Dec 10, 2012.